{"id":"hydroxyzine-pamoate","_fda":{"id":"638cf29d-9dc9-4a80-8937-ba3811482f08","set_id":"02616eee-a1a4-4afc-b84e-69fd28755138","openfda":{"unii":["M20215MUFR"],"route":["ORAL"],"rxcui":["995253"],"spl_id":["638cf29d-9dc9-4a80-8937-ba3811482f08"],"brand_name":["hydroxyzine pamoate"],"spl_set_id":["02616eee-a1a4-4afc-b84e-69fd28755138"],"package_ndc":["63629-8874-1"],"product_ndc":["63629-8874"],"generic_name":["HYDROXYZINE PAMOATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["HYDROXYZINE PAMOATE"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA087479"],"original_packager_product_ndc":["0185-0674"]},"version":"105","warnings":["WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers."],"overdosage":["OVERDOSAGE The most common manifestation of overdosage of hydroxyzine pamoate is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and vasopressors ( do not use epinephrine as hydroxyzine counteracts its pressor action ). Caffeine and Sodium Benzoate Injection, USP, may be used to counteract central nervous system depressant effects. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes. ECG monitoring is recommended in cases of hydroxyzine overdose. There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration."],"description":["DESCRIPTION Hydroxyzine pamoate is a light yellow, practically odorless powder practically insoluble in water and methanol and freely soluble in dimethylformamide. It is chemically designated as (±)-2-[2-[4-( p -Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol 4,4’-methylenebis[3-hydroxy-2-naphthoate] (1:1) [10246-75-0] and can be structurally represented as follows: C 21 H 27 CIN 2 O 2 •C 23 H 16 O 6 M.W. 763.27 Each capsule, for oral administration, contains hydroxyzine pamoate equivalent to hydroxyzine hydrochloride 25 mg or 50 mg. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, sodium starch glycolate (potato), and sodium lauryl sulfate. The capsule shell contains the following ingredients: D&C Yellow #10, FD&C Green #3, FD&C Yellow #6, gelatin, and titanium dioxide. The edible imprinting ink contains the following ingredients: black iron oxide, D&C Yellow #10, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, propylene glycol, and shellac glaze."],"precautions":["PRECAUTIONS THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced. Since drowsiness may occur with use of the drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine pamoate. Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased. QT Prolongation/Torsade de Pointes (TdP) Cases of QT prolongation and Torsade de Pointes have been reported during post-marketing use of hydroxyzine. The majority of reports occurred in patients with other risk factors for QT prolongation/TdP (pre-existing heart disease, electrolyte imbalances or concomitant arrhythmogenic drug use). Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias. Caution is recommended during the concomitant use of drugs known to prolong the QT interval. These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol). Acute Generalized Exanthematous Pustulosis (AGEP) Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema. Inform patients about the signs of AGEP, and discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity. If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity. Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine pamoate included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine pamoate has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine pamoate and observed closely."],"how_supplied":["HOW SUPPLIED Hydroxyzine Pamoate Capsules, USP, for oral administration, are available as 25 mg (equivalent to 25 mg hydroxyzine hydrochloride) are light green/dark green capsules imprinted “E 613” and supplied as: NDC: 63629-8874-1 bottles of 500 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. KEEP TIGHTLY CLOSED. KEEP OUT OF THE REACH OF CHILDREN. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine pamoate included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine pamoate has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine pamoate and observed closely."],"effective_time":"20241216","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers."],"adverse_reactions":["ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature. Skin and Appendages Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post-marketing reports. Anticholinergic Dry mouth. Central Nervous System Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System QT prolongation, Torsade de Pointes. In post-marketing experience, the following additional undesirable effects have been reported: Body as a Whole Allergic reaction Nervous System Headache Psychiatric Hallucination Skin and Appendages Pruritus, rash, urticaria"],"contraindications":["CONTRAINDICATIONS Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy. Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine pamoate is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication. Hydroxyzine is contraindicated in patients with known hypersensitivity to hydroxyzine products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity. Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine pamoate clinical effects are usually noted within 15 to 30 minutes after oral administration."],"indications_and_usage":["INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."],"spl_unclassified_section":["25 mg and 50 mg Rx Only"],"dosage_and_administration":["DOSAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 mg to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses. As a sedative when used as a premedication and following general anesthesia: 50 mg to 100 mg in adults, and 0.6 mg/kg in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all medications, the dosage should be adjusted according to the patient’s response to therapy."],"spl_product_data_elements":["hydroxyzine pamoate hydroxyzine pamoate HYDROXYZINE PAMOATE HYDROXYZINE HYDROXYZINE DIHYDROCHLORIDE SILICON DIOXIDE D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C BLUE NO. 2 FD&C GREEN NO. 3 FD&C YELLOW NO. 6 FD&C RED NO. 40 FERROSOFERRIC OXIDE GELATIN, UNSPECIFIED HYDROXYPROPYL CELLULOSE (1200000 WAMW) LACTOSE MONOHYDRATE MAGNESIUM STEARATE PROPYLENE GLYCOL SHELLAC SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO TITANIUM DIOXIDE light green/dark green E613 Chemical Structure"],"package_label_principal_display_panel":["Hydroxyzine Pamoate 25 mg Caps #500 Label"]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Drowsiness","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Allergic reaction","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Hydroxyzine is contraindicated in early pregnancy due to insufficient clinical data and observed fetal abnormalities in animals at high doses.","Hydroxyzine is contraindicated in patients with a prolonged QT interval.","Hydroxyzine pamoate is contraindicated in patients with a previous hypersensitivity to any component of this medication.","Hydroxyzine is contraindicated in patients with known hypersensitivity to hydroxyzine products, cetirizine hydrochloride, or levocetirizine hydrochloride."],"seriousAdverseEvents":[{"effect":"Torsade de Pointes","drugRate":"","severity":"serious"},{"effect":"QT prolongation","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Tremor","drugRate":"","severity":"serious"},{"effect":"Involuntary motor activity","drugRate":"","severity":"serious"},{"effect":"Acute Generalized Exanthematous Pustulosis (AGEP)","drugRate":"","severity":"serious"},{"effect":"Fixed drug eruptions","drugRate":"","severity":"serious"},{"effect":"Hallucination","drugRate":"","severity":"serious"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HYDROXYZINE PAMOATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:09:38.023565+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:10:21.616907+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:09:43.769588+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDROXYZINE PAMOATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:09:44.101932+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:09:36.907549+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:10:16.877657+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:09:36.907582+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:09:45.219796+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200467/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:09:44.871688+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature. Skin and Appendages Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post-marketing reports. Anticholinergic Dry mouth. Central Nervous System Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, inc","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:09:50.454287+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:09:57.541289+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA087479","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:09:36.907586+00:00"}},"_dailymed":{"setId":"98a1c161-5728-4626-a6b0-5414935e4eef","title":"HYDROXYZINE PAMOATE CAPSULE [PD-RX PHARMACEUTICALS, INC.]"},"aiSummary":"Hydroxyzine pamoate is a marketed drug primarily indicated for the treatment of anxiety and tension in psychoneurosis. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of exclusivity post-patent expiry, which could significantly impact market share and revenue.","_scrapedAt":"2026-03-27T23:40:15.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T04:10:21.616988+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"hydroxyzine-pamoate-anxiety-and-tension-in-psychon","name":"Anxiety and tension in psychoneurosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with psychoneurosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with psychoneurosis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"hydroxyzine-pamoate-adjunct-in-organic-disease-sta","name":"Adjunct in organic disease states with anxiety","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with organic disease states and anxiety","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with organic disease states and anxiety","diagnosticRequired":null,"brandNameForIndication":""},{"id":"hydroxyzine-pamoate-management-of-pruritus-due-to-","name":"Management of pruritus due to allergic conditions","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pruritus due to allergic conditions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pruritus due to allergic conditions","diagnosticRequired":null,"brandNameForIndication":""},{"id":"hydroxyzine-pamoate-sedation-for-premedication-and","name":"Sedation for premedication and post-anesthesia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing procedures requiring premedication or general anesthesia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing procedures requiring premedication or general anesthesia","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07472413","phase":"PHASE3","title":"Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-07-01","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder","enrollment":524},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02535416","phase":"PHASE1","title":"A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT03808805","phase":"PHASE3","title":"Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2019-04-16","conditions":"Myeloproliferative Disorder, Aquagenic Pruritus","enrollment":63},{"nctId":"NCT07236372","phase":"NA","title":"Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","status":"NOT_YET_RECRUITING","sponsor":"University of Phayao","startDate":"2025-11","conditions":"Acute Urticaria","enrollment":140},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT05946551","phase":"PHASE3","title":"Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial","status":"TERMINATED","sponsor":"Emory University","startDate":"2024-03-08","conditions":"COVID-19","enrollment":5},{"nctId":"NCT04814381","phase":"PHASE4","title":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2021-09-15","conditions":"Refractory Chronic Cluster Headache","enrollment":90},{"nctId":"NCT06080100","phase":"EARLY_PHASE1","title":"RELIEF OF PSYCHOEMOTIONAL STRESS USING XENON SEDATION","status":"RECRUITING","sponsor":"The S.N. Fyodorov Eye Microsurgery State Institution","startDate":"2023-11-01","conditions":"Psychological Stress, Anesthesia, Anxiety","enrollment":140},{"nctId":"NCT07031206","phase":"PHASE2","title":"Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-07-01","conditions":"Anxiety, Pain","enrollment":152},{"nctId":"NCT06890260","phase":"NA","title":"The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife","status":"RECRUITING","sponsor":"Pengfei Qiu","startDate":"2025-04-11","conditions":"Allergic Rhinitis (Disorder), Electroacupuncture, Microneedle Knife","enrollment":90},{"nctId":"NCT06819774","phase":"PHASE3","title":"Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria","status":"RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-04-22","conditions":"Acute Urticaria","enrollment":284},{"nctId":"NCT05042479","phase":"NA","title":"Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology.","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2022-06-30","conditions":"Hematologic Malignancy, Hematologic Non Malignancy, Solid Tumor, Childhood","enrollment":34},{"nctId":"NCT06754410","phase":"PHASE3","title":"Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study","status":"COMPLETED","sponsor":"South Valley University","startDate":"2021-03-01","conditions":"Lower Ureteric Stones","enrollment":480},{"nctId":"NCT03167216","phase":"EARLY_PHASE1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-08-01","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":20},{"nctId":"NCT05126459","phase":"PHASE3","title":"A Comparison of Oral Sedation-related Events of Three Multiagent Oral Sedation Regimens in Pediatric Dental Patients","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2022-02-14","conditions":"Anxiety, Dental, Dental Decay","enrollment":60},{"nctId":"NCT06039137","phase":"","title":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":"Solid Tumor","enrollment":395},{"nctId":"NCT04609956","phase":"NA","title":"Virtual Reality Technology on Pain Perception and Anxiety Levels in Adolescents and Young Adults During Third Molar Germ Avulsion Surgery (VIDAMO)","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2021-02-16","conditions":"Anxiety, Dental","enrollment":100},{"nctId":"NCT00751218","phase":"PHASE4","title":"A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05-06","conditions":"Urticaria","enrollment":174},{"nctId":"NCT00751166","phase":"PHASE4","title":"A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Urticaria","enrollment":149},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT04071821","phase":"PHASE1","title":"Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg","status":"NOT_YET_RECRUITING","sponsor":"Seattle Gummy Company","startDate":"2025-05-01","conditions":"Allergy","enrollment":30},{"nctId":"NCT00650065","phase":"PHASE1","title":"Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT00649857","phase":"PHASE1","title":"Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04990388","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-10-18","conditions":"Glycogen Storage Disease Type III","enrollment":9},{"nctId":"NCT05095311","phase":"PHASE4","title":"The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-05-19","conditions":"Exercise-induced Arterial Hypoxemia","enrollment":16},{"nctId":"NCT02023164","phase":"PHASE3","title":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2013-07","conditions":"Acute Urticaria","enrollment":36},{"nctId":"NCT06126991","phase":"PHASE1, PHASE2","title":"Organ Protective Effect of Cetirizine In Patients With Severe Burns","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-01-23","conditions":"Burns","enrollment":32},{"nctId":"NCT04068948","phase":"PHASE4","title":"Comparing Pediatric Dental Oral Sedation Outcomes With and Without Meperidine in Children Aged 3-7 Years","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-06-25","conditions":"Dental Caries in Children, Pediatric Dental Sedation, Meperidine","enrollment":37},{"nctId":"NCT05680584","phase":"PHASE1","title":"Comparison Between Oral Melatonin and Hydroxyzine in Pediatric Patients Undergoing Adenotonsillectomy","status":"UNKNOWN","sponsor":"Minia University","startDate":"2023-02-01","conditions":"Effect of Drug, Anxiety","enrollment":78},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT03453632","phase":"PHASE2, PHASE3","title":"Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-06-14","conditions":"Epidermolysis Bullosa Simplex","enrollment":25},{"nctId":"NCT02865018","phase":"PHASE1, PHASE2","title":"Neuromyelitis Optica (NMO) & Cetirizine","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-04","conditions":"Neuromyelitis Optica","enrollment":16},{"nctId":"NCT04280965","phase":"EARLY_PHASE1","title":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-02-01","conditions":"Post Traumatic Stress Disorder","enrollment":28},{"nctId":"NCT04188106","phase":"PHASE4","title":"Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment","status":"COMPLETED","sponsor":"Rose Research Center, LLC","startDate":"2019-06-17","conditions":"Smoking Cessation, Stress, Sleep Disturbance","enrollment":26},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT04481412","phase":"PHASE2, PHASE3","title":"Topical Cetirizine in Androgenetic Alopecia in Females","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-25","conditions":"Androgenetic Alopecia","enrollment":66},{"nctId":"NCT03158376","phase":"PHASE3","title":"Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2015-09","conditions":"Postoperative Pain, Chronic Pain","enrollment":201},{"nctId":"NCT03340740","phase":"PHASE4","title":"The Effect of Cetirizine on Bronchoconstriction","status":"COMPLETED","sponsor":"New York City Health and Hospitals Corporation","startDate":"2018-05-11","conditions":"Allergic Rhinitis, Asthma","enrollment":40},{"nctId":"NCT05492812","phase":"NA","title":"Sedation and Nursing Management in EEG Recording in Children","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2021-01-01","conditions":"Electroencephalography, Melatonin, Chloral Hydrate","enrollment":180},{"nctId":"NCT00794846","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":124},{"nctId":"NCT00794599","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":118},{"nctId":"NCT00794495","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":122},{"nctId":"NCT00794794","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":204},{"nctId":"NCT00794378","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":202},{"nctId":"NCT00780403","phase":"PHASE4","title":"Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Allergies","enrollment":220},{"nctId":"NCT00779116","phase":"PHASE4","title":"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Allergies","enrollment":217},{"nctId":"NCT05224167","phase":"NA","title":"Melatonin Versus Hydroxizin for Pre Operative Anxiety in Elderly Patients With Hip Fracture","status":"UNKNOWN","sponsor":"Mongi Slim Hospital","startDate":"2022-03-01","conditions":"Preoperative Anxiety","enrollment":50},{"nctId":"NCT03772158","phase":"PHASE1","title":"Cetirizine Chewable Bioequivalence and Food Effect Study","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2018-12-11","conditions":"Allergy","enrollment":40},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT04836806","phase":"PHASE4","title":"Cetirizine and Famotidine for COVID-19","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2021-08","conditions":"Covid19","enrollment":""},{"nctId":"NCT04237090","phase":"PHASE3","title":"Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2020-02-14","conditions":"Breast Cancer, Lung Cancer, Ovarian Cancer","enrollment":27},{"nctId":"NCT03324828","phase":"PHASE4","title":"Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)","status":"TERMINATED","sponsor":"Hospital San Carlos, Madrid","startDate":"2017-11-01","conditions":"Anxiety","enrollment":170},{"nctId":"NCT03192488","phase":"PHASE4","title":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-08-31","conditions":"Hypoxia, Altitude","enrollment":13},{"nctId":"NCT04293822","phase":"PHASE4","title":"Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT04184141","phase":"PHASE4","title":"Preoperative Use of Alprazolam and Hydroxyzine in Anxiety","status":"UNKNOWN","sponsor":"Istanbul Medeniyet University","startDate":"2019-12-01","conditions":"Agitation on Recovery From Sedation","enrollment":90},{"nctId":"NCT03806270","phase":"","title":"Hydroxyzine Dihydrochloride Premedication is a Necessity for Strabismus Surgery","status":"COMPLETED","sponsor":"Yeditepe University","startDate":"2018-10-01","conditions":"Strabismus, Reflex, Oculocardiac, Hydroxyzine","enrollment":45},{"nctId":"NCT03047278","phase":"PHASE4","title":"Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.","status":"COMPLETED","sponsor":"Natalia Valadares de Moraes","startDate":"2015-11-01","conditions":"Neuropathic Pain, Type 2 Diabetes Mellitus, Diabetic Neuropathy, Painful","enrollment":29},{"nctId":"NCT01241214","phase":"PHASE2","title":"Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2010-11","conditions":"Seasonal Allergic Rhinitis","enrollment":579},{"nctId":"NCT02543346","phase":"PHASE4","title":"Comparability and Standardization of Controlled Allergen Challenge Facilities","status":"COMPLETED","sponsor":"Queen's University","startDate":"2015-10","conditions":"Allergic Rhinitis","enrollment":98},{"nctId":"NCT03728894","phase":"PHASE3","title":"Oral Sedation With and Without Nitrous Oxide","status":"COMPLETED","sponsor":"Tishreen University","startDate":"2018-11-17","conditions":"Behavior, Child","enrollment":30},{"nctId":"NCT01825655","phase":"PHASE4","title":"Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2014-09","conditions":"Pruritus","enrollment":3},{"nctId":"NCT01484119","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2011-12","conditions":"Seasonal Allergic Rhinitis","enrollment":630},{"nctId":"NCT00291642","phase":"PHASE2","title":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":551},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01495338","phase":"PHASE1","title":"A Comparison of the Safety and Comfort of AC-170","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-12","conditions":"Normal Ocular Health","enrollment":60},{"nctId":"NCT02756624","phase":"PHASE3","title":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":516},{"nctId":"NCT00490204","phase":"PHASE3","title":"Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-27","conditions":"Rhinitis, Allergic, Perennial","enrollment":239},{"nctId":"NCT02447393","phase":"PHASE1","title":"Phase 1 Study of Levocetirizine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-18","conditions":"Dermatitis","enrollment":20},{"nctId":"NCT00972504","phase":"PHASE2","title":"723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT02613910","phase":"PHASE3","title":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-12-23","conditions":"Pemphigus","enrollment":1},{"nctId":"NCT01622283","phase":"PHASE1","title":"Pharmacokinetic Study of Levocetirizine Oral Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-02","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":20},{"nctId":"NCT00661674","phase":"NA","title":"Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-04","conditions":"Substance-Related Disorders","enrollment":10},{"nctId":"NCT02932774","phase":"PHASE4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2001-03","conditions":"Allergic Rhinitis, Hay Fever, SAR","enrollment":683},{"nctId":"NCT01501591","phase":"NA","title":"Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2012-11","conditions":"Placebo Effect, Placebo Drug Interaction","enrollment":480},{"nctId":"NCT01557712","phase":"PHASE3","title":"Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2012-03","conditions":"Major Depressive Disorder","enrollment":25},{"nctId":"NCT01103050","phase":"PHASE2","title":"A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-22","conditions":"Allergic Rhinitis","enrollment":60},{"nctId":"NCT01372670","phase":"PHASE4","title":"Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder","status":"WITHDRAWN","sponsor":"HealthPartners Institute","startDate":"2012-01","conditions":"Anxiety in Those Patients With Anorexia Nervosa, Eating Disorder Not Otherwise Specified, BMI (<=18)","enrollment":""},{"nctId":"NCT00851344","phase":"PHASE2","title":"Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT01675986","phase":"PHASE2","title":"Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"","conditions":"Feeling Anxious","enrollment":306},{"nctId":"NCT02814981","phase":"","title":"Hydroxyzine and Risk of Prolongation of QT Interval","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2015-11","conditions":"Hydroxyzine, Long QT Syndrome","enrollment":130},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT00260481","phase":"PHASE2, PHASE3","title":"Prometa Pharmacotherapy for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-01","conditions":"Drug Abuse, Drug Dependence","enrollment":120},{"nctId":"NCT01985789","phase":"PHASE4","title":"Anti-histamines and Methacholine Challenges.","status":"COMPLETED","sponsor":"Don Cockcroft","startDate":"2013-11","conditions":"Asthma","enrollment":12},{"nctId":"NCT01151696","phase":"PHASE4","title":"Pain and Anxiety Management of Traumatic Emergency in a Pre-hospital Setting","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2010-05","conditions":"Pain","enrollment":140},{"nctId":"NCT01981499","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Migraine","enrollment":31},{"nctId":"NCT01748344","phase":"PHASE2","title":"Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2012-11","conditions":"Seasonal Allergic Rhinitis","enrollment":58},{"nctId":"NCT00826943","phase":"PHASE4","title":"Is Levocetirizine Less Sedating Than Cetirizine?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-01","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT01940393","phase":"PHASE4","title":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","status":"COMPLETED","sponsor":"Grupo de Alergología Clínica y Experimental","startDate":"2013-08","conditions":"Urticaria","enrollment":150},{"nctId":"NCT01318681","phase":"NA","title":"Rhinitis, Cognition and Driving Performance","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-01","conditions":"Seasonal Allergic Rhinitis, Driving Ability, Cognition","enrollment":22},{"nctId":"NCT01496911","phase":"PHASE4","title":"Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving","status":"COMPLETED","sponsor":"Utrecht Institute for Pharmaceutical Sciences","startDate":"2012-04","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01781507","phase":"PHASE4","title":"Study of Bronchodilation Effects of Cetirizine","status":"COMPLETED","sponsor":"California Allergy and Asthma Medical Group, Inc.","startDate":"2011-06","conditions":"Allergic Rhinitis, Asthma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[{"count":281,"reaction":"DRUG INEFFECTIVE"},{"count":275,"reaction":"COMPLETED SUICIDE"},{"count":217,"reaction":"NAUSEA"},{"count":213,"reaction":"FATIGUE"},{"count":197,"reaction":"DRUG HYPERSENSITIVITY"},{"count":187,"reaction":"PAIN"},{"count":173,"reaction":"ANXIETY"},{"count":170,"reaction":"HEADACHE"},{"count":155,"reaction":"PRURITUS"},{"count":145,"reaction":"RASH"}],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL1200467"},"_approvalHistory":[{"date":"20000229","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19991230","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19941011","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20030103","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19871116","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19981201","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20011109","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19870331","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19980709","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19950112","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19960410","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19910816","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19900104","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20210216","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20011109","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19991221","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19941223","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19990520","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19920403","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20020429","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19871116","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19980918","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19840615","type":"ORIG","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19920403","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19960920","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19910816","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19910509","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19840925","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20210216","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20071009","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19900104","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"20150124","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088487"},{"date":"19990611","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19941223","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20030103","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19981116","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19920403","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20011109","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19981116","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19920403","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19960920","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19871118","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19950112","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19840615","type":"ORIG","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19900104","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20150124","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20210216","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20110727","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19991221","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19990520","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19941011","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20020429","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19981201","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20011109","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19981116","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19871118","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19950112","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19960410","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19870331","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19910509","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19890912","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19840925","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20210216","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20000203","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"20080528","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA088488"},{"date":"19941223","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19990520","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19920403","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20020429","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19871118","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19980915","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19840615","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19920403","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19960920","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19910816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19910509","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19840925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20150124","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20210216","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20110727","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20000229","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19990923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19941011","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20030103","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19981201","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20011109","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19871118","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19980709","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19950112","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19960410","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19910816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19900104","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20210216","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20011109","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20080616","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"19991221","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA088496"},{"date":"20210216","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19941209","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19860307","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19950303","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20000202","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19941212","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19960412","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19941212","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19890509","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20150124","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20210216","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19960522","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19950303","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20130627","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19860307","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20021220","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19811214","type":"ORIG","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19920812","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19960624","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"19941209","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA087479"},{"date":"20130603","type":"ORIG","sponsor":"HERITAGE PHARMA","applicationNumber":"ANDA201507"},{"date":"20150124","type":"SUPPL","sponsor":"HERITAGE PHARMA","applicationNumber":"ANDA201507"},{"date":"20130711","type":"SUPPL","sponsor":"HERITAGE PHARMA","applicationNumber":"ANDA201507"}],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"HYDROXYZINE PAMOATE","genericName":"HYDROXYZINE PAMOATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1959","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T04:10:21.616988+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}